Myasthenia gravis in South Africans: Racial differences in clinical manifestations

Neuromuscular Disorders

Volumn 17, Issue 11-12, 2007, Pages 929-934

  Heckmann, J M ^a   Owen, E P ^b   Little, F ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Africa; Black; Complete ophthalmoplegia; Myasthenia gravis; Ocular; Race

Indexed keywords

AZATHIOPRINE; CHOLINERGIC RECEPTOR ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EDROPHONIUM; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; PREDNISONE; PYRIDOSTIGMINE;

ADULT; AGED; ARTICLE; CAUCASIAN; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; NEGRO; OPHTHALMOPLEGIA; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PTOSIS; RACE DIFFERENCE; SOUTH AFRICA; THYMECTOMY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE OF ONSET; AUTOANTIBODIES; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, NATURAL; IMMUNOSUPPRESSION; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; OPHTHALMOPLEGIA; PHENOTYPE; RECEPTORS, CHOLINERGIC; SOUTH AFRICA; THYMECTOMY;

EID: 36349030431     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2007.07.002     Document Type: Article

References (32)

1. Phillips II L.H. The epidemiology of myasthenia gravis. Ann N Y Acad Sci 998 (2003) 407-412
2. Bateman K, Schinkel M, Little F, Liebenberg L, Vincent A, Heckmann JM. Incidence of seropositive myasthenia gravis in Cape Town and South Africa. S Afr Med J 2007, in press.
3. Heckmann J.M., LeePan E.B., and Eastman R.W. High-dose immunosuppressive therapy in generalized myasthenia gravis- a 2-year follow-up study. S Afr Med J 91 (2001) 765-770
4. Tindall R.S.A., Rollins J.A., Phillips J.T., et al. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in Myasthenia Gravis. N Engl J Med 316 (1987) 719-724
5. Jaretzki III A., Barohn R.J., Ernsthoff R.M., et al. (Task force of the medical scientific advisory board of the myasthenia gravis Foundation of America). Myasthenia gravis. Recommendations for clinical research standards. Neurology 55 (2000) 16-23
6. Oosterhuis H.J.G.H. Clinical aspects & diagnosis and differential diagnosis. In: De Baets M.H., and Oosterhuis H.J.G.H. (Eds). Myasthenia gravis (1993), CRC Press, Boca Raton
7. Gustavo de Feo L., Schottlender J., Martelli N.A., and Molfino N.A. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 26 (2002) 31-36
8. Villalba L., Hicks J.E., Adams E.M., Sherman J.B., Gourley M.F., Leff R.L., et al. Treatment of refractory Myositis. A randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 41 3 (1998) 392-399
9. Holt I.J., Cooper J.M., Morgan-Hughes J.A., and Harding A.E. Deletions of muscle mitochondrial DNA. Lancet 1 (1988) 236-240
10. Moraes C.T., DiMauro S., Zeviani M., et al. Mitochondrial deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med 320 (1989) 1293-1299
11. Anderson S., Bankier A.T., Barrel B.G., et al. Sequence and organization of the human mitochondrial genome. Nature 290 (1981) 457-465
12. Compston D.A.S., Vincent J., Newsom-Davis J., and Batchelor J.R. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103 (1980) 579-601
13. Chui H.-C., Vincent J., Newsom-Davis J., et al. Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology 37 (1987) 1854-1857
14. Kawaguchi N., Kuwabara S., Nemoto Y., et al. Treatment and outcome of myasthenia gravis: retrospective multi-center analysis of 470 Japanese patients, 1999-2000. J Neurol Sci 224 (2004) 43-47
15. Zhang X., Yang M., Xu J., et al. Clinical and serological study of myasthenia gravis in HuBei province, China. J Neurol Neurosurg Psychiatry 78 (2007) 386-390
16. Andrews P.I., Massey J.M., Howard J.F., and Sanders D.B. Race, sex and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology 44 (1994) 1208-1214
17. Chakraborty R., Kamboh M.I., and Ferrel R.E. "Unique" alleles in admixed populations: a strategy for determining "hereditary" population differences of disease frequencies. Ethn Dis 1 (1991) 245-256
18. Heckmann J.M., Lambson E.M.T., Little F., and Owen E.P. Thiopurine methytransferase (TPMT) heterozygosity and enzyme activity as predictive tests for the development of azathioprine-related adverse events. J Neurol Sci 231 (2005) 71-80
19. Kaminski H.J., Li Z., Richmonds C., et al. Susceptibility of ocular tissues to autoimmune diseases. Ann N Y Acad Sci 998 (2003) 362-374
20. Daroff R.B. Ocular myasthenia:diagnosis and therapy. In: Glaser L.J. (Ed). Neuroophthalmology (1980), CV Mosby, St Louis
21. Kupersmith M.J. Does early Immunotherapy reduce the conversion of ocular myasthenia gravis to generalized myasthenia gravis? (Editorial). J Neuro-Ophthalmol 23 4 (2003) 249-250
22. Jacobsen D.M. Acetylcholine receptor antibodies in patient with Graves' ophthalmopathy. J Neuro-Ophthalmol 15 (1995) 166-170
23. Keane J.R. Acute bilateral ophthalmoplegia: 60 cases. Neurology 36 (1986) 279-281
24. Mullaney P., Vajsar J., Smith R., and Buncic J.R. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children. Ophthalmology 107 (2000) 504-510
25. Kim J.-H., Hwang J.-M., Hwan Y.S., et al. Childhood ocular myasthenia gravis. Ophthalmology 110 (2003) 1458-1462
26. Bradley E.A., Bartley G.B., Chapman K., and Waller R.R. Surgical correction of blepharoptosis in patient with myasthenia gravis. Ophthal Plast Reconstr Surg 17 (2001) 103-110
27. Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromusc Dis 16 (2006) 459-467
28. Ramos-Casals M., Garcia-Carraso M., Brito M.P., et al. Autoimmuntiy and geriatrics: clinical significance of autoimmune manifestations in the elderly. Lupus 12 (2003) 341-355
29. Aarli J.A., Romi F., Skeie G.O., and Gilhus N.E. Myasthenia gravis in individuals over 40. Ann N Y Acad Sci 998 (2003) 424-431
30. Evoli A., Tonali P.A., Padua L., et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126 (2003) 2304-2311
31. Kaminski H.J., Li Z., Richmonds C., et al. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp Neurol 189 (2004) 333-342
32. Chamberlain-Banoub J., Neal J.W., Mizuno M., Harris C.L., and Morgan B.P. Complement membrane attack is required for end plate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol 146 (2006) 278-286